In children, pelvic-floor biofeedback (an EMG sensor with an animated display) is the reference treatment for dysfunctional voiding: it improves flow and bladder emptying, reduces urinary infections, and did better than behavioural therapy alone in refractory bedwetting — without medication side effects. For the number of wetting episodes itself, the advantage over well-supervised urotherapy is less clear. Neurofeedback has only a single small study.
AAPB2Possibly efficaciousNeuroLogic2Possibly efficacioussame vs AAPB
Level 2 maintained (the AAPB's own text withholds a conclusion; the mapped AAPB level is 2). A single randomised trial: Khazaei 2015, n = 30 children aged 5-10 with primary enuresis, three arms all on imipramine — beta/theta neurofeedback, sham neurofeedback (a confederate's recorded signal) or medication only — 10 sessions of 30 minutes over 5 weeks; the frequency of dysfunctional voiding fell significantly in all three arms with no between-group difference after the intervention or at 3 months. The adult origin is four case reports (Hammond 2005). No neurofeedback study in the 2022-2026 window. Ten sessions are below the dose of clinical amplitude training, the sample is far too small to detect a difference from an active drug, and a sham-null result is not disqualifying (Parsons 2026); the level therefore stays at 2 rather than 1, but there is no basis for more. Adolescents are covered only by extrapolation.
Biofeedback
Surface or intra-anal pelvic-floor EMG biofeedback — dysfunctional voiding, daytime incontinence and refractory nocturnal enuresis
Ages
Child (under 12) · Adolescent (12-17)
Techniques
Pelvic-floor EMG
AAPB4EfficaciousNeuroLogic4Efficacioussame vs AAPB
Level 4 maintained (age-pooled: the trials enrol children of 5-16 years, mean ages 6-10, with no separate adolescent analysis). Randomised superiority over urotherapy or behavioural therapy alone in independent settings: Abd El-Moghny 2018 (n = 90, refractory monosymptomatic nocturnal enuresis, intra-anal biofeedback plus behavioural therapy: 60 % partial responders vs 23.3 % with behavioural therapy alone; electrical stimulation 86.7 %) and the dysfunctional-voiding RCTs pooled by Passos 2025 (4 RCTs, n = 244: higher Qmax, MD 4.69 mL/s; normalised flow pattern, RR 2.70; lower post-void residual; enuresis improved, RR 2.34) and Qi 2022 (7 RCTs, n = 539, vs standard urotherapy: fewer urinary tract infections, RR 1.71, lower residual, better voiding pattern and EMG, less constipation — but no significant difference in daytime, RR 1.20, or night-time incontinence). No significant difference from bona fide comparators — alpha-blocker (Yucel 2005), pelvic floor exercises (Vasconcelos 2006, n = 56) — and inferiority to electrical stimulation in enuresis. The 2022-2026 window adds mainly uncontrolled service cohorts (Yener 2025, n = 779, response after a mean of 6 sessions; Das 2023, n = 490) and one three-arm RCT without a biofeedback-free control (Ibrahim Elgohary 2025, n = 117). Biofeedback is the established treatment of dysfunctional voiding; for incontinence episodes as such, the added value over supervised urotherapy is less consistent, and Level 5 is not reached (no sham, no superiority over a reference treatment).
By age
Adolescent (12-17)
Adolescents are included in the paediatric trials (up to 14-16 years) but never analysed separately; the levels shown are those of the pooled child-adolescent evidence.
In short
Clinical reading
EMG biofeedback: AAPB Level 4; NeuroLogic 4 (same), age-pooled. Randomised superiority over behavioural therapy or urotherapy alone (Abd El-Moghny 2018; meta-analyses Passos 2025, 4 RCTs, and Qi 2022, 7 RCTs: flow, residual, infections, no significant effect on daytime incontinence); no difference from alpha-blocker or exercises alone; no sham. Neurofeedback: AAPB Level 2; NeuroLogic 2 (same) — Khazaei 2015 (n = 30, 10 sessions), improvement in all arms, no difference from sham or from medication.
Protocols
Perineal surface EMG (electrodes at 3 and 9 o'clock, abdominal or thigh reference) delivered as age-appropriate animated games, learning to relax the pelvic floor during voiding, home exercises and parental involvement; 5-10 weekly sessions, with gains plateauing after 8-11 sessions (Das 2023, Yener 2025).
Limits
No sham-controlled trial; unblinded outcomes; meta-analyses show no significant effect on daytime or night-time incontinence episodes versus urotherapy; heterogeneous presentations (nocturnal enuresis, dysfunctional voiding, overactive bladder) and adolescents not analysed separately; neurofeedback research nearly non-existent.
Study base
Five RCTs and a dozen quasi-experimental studies in the AAPB base; 2022-2025 meta-analyses (Qi, Li, Passos); a single neurofeedback study. 2022-2026 base: 17 publications indexed in the archive (1 RCT, 1 controlled trial, 5 meta-analyses, 1 systematic review, 9 cohorts), all biofeedback.
Brendan's perspective
Two rows, both unchanged. Biofeedback stays at level 4: it is the established training for dysfunctional voiding — Passos 2025 and Qi 2022 give better flow, lower residual volume and fewer urinary infections — but Qi finds no significant difference in daytime or night-time wetting against supervised urotherapy, there is no sham trial and no superiority over a reference treatment, so level 5 is not earned. Abd El-Moghny 2018, in refractory bedwetting, is the exception worth knowing. Neurofeedback stays at level 2 on one trial: Khazaei 2015, thirty children, every arm on imipramine, ten sessions. Ten sessions is half a clinical course, and a null against sham is not a null — sham is a partially active comparator (Parsons 2026). The study is simply too small to say anything. The division of labour I would work to: biofeedback is the tool for the incontinence itself — it addresses the mechanical side of voiding and it has been tested — so the family goes to pelvic floor work first, and I would not offer neurofeedback in its place. Where I think neurofeedback can earn a place is one step back from the bladder. Where emotional regulation is part of the picture, training it can produce secondary gains that reach the continence problem without being aimed at it. Enuresis specifically is worth thinking about along those lines: if neurofeedback improves a child's sleep — and sleep is what it moves most reliably across my whole practice — then it is entirely possible that night-time wetting improves with it. That is a mechanism worth testing, and I offer it as a hypothesis rather than as something I can demonstrate. This is another corner of the field with very little research and a real need for more.
Ladi-Seyedian et al. (2019) Pelvic floor electrical stimulation and muscles training combined with biofeedback in children with voiding dysfunction doi:10.1016/j.jpedsurg.2018.06.007
Khazaei et al. (2015) The effect of neurofeedback therapy in primary enuretic children doi:10.4236/wjns.2015.52010
Abd El-Moghny et al. (2018) Effectiveness of intra-anal biofeedback and electrical stimulation in the treatment of children with refractory monosymptomatic nocturnal enuresis: A comparative randomized controlled trial doi:10.5213/inj.1836142.071
Passos et al. (2025) Efficacy of Electromyographic Biofeedback for Dysfunctional Voiding in Children and Adolescents: A Systematic Review and Meta-analysis of Randomized Trials doi:10.1016/j.urology.2025.08.046
Qi et al. (2022) The effect of biofeedback treatment for children with non-neurogenic voiding dysfunction: A systematic review and meta-analysis doi:10.1002/nau.24886
